Paul Tudor Jones’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Paul Tudor Jones’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-22,989	Closed	-$2.47M	–	3070
2023 Q1	$2.47M	Buy	22,989 +2,386	+12%	+$275K	0.04%	675
2022 Q4	$2.27M	Buy	20,603 +413	+2%	+$26.8K	0.04%	568
2022 Q3	$1.19M	Buy	+20,190	New	+$924K	0.03%	806

Other funds holding RXDX

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Paul Tudor Jones's RXDX Position: Q2 2023 in Review

Paul Tudor Jones sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 22,989 shares — an estimated $2.47M sold.

Paul Tudor Jones first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $2.47M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Paul Tudor Jones reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Paul Tudor Jones sold 22,989 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $2.47M.
Paul Tudor Jones first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Paul Tudor Jones's Prometheus Biosciences, Inc. Common Stock position peaked at $2.47M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Tudor Investment Corp's 13F filing for Q2 2023, filed 14 Aug 2023.